Chinese biotech firm Kintor Pharmaceutical Limited saw its stock price jump by more than 20% the day after it announced on April 25 that it had "completed the first patient enrollment and dosing" in a late-stage U.S. clinical trial of its experimental COVID-19 treatment. Kintor's lack of transparency, along with inconsistencies in the company's statements, raise a "red flag" about …
Sign up to our free weekly newsletter for insider tips and product reviews from our shopping experts Sign up for our free IndyBest email Sign up for our free IndyBest email SIGN UP I would like to be emailed about offers, events and updates from The Independent. “So, I wanted to put together a kit for you guys that would …
